Pharm Country

RenovaCare Announces New Corporate Headquarters and Laboratory Facilities

March 11, 2020 | 6 min read

RenovaCare, Inc. today announced new corporate headquarters in Roseland, New Jersey and laboratory facilities in Berlin, Germany to advance the development of its patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues.

ROSELAND, N.J., March 11, 2020 (GLOBE NEWSWIRE) -- Renovacare, Inc. (Symbol: RCAR; www.renovacareinc.com), today announced new corporate headquarters in Roseland, New Jersey and laboratory facilities in Berlin, Germany to advance the development of its patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues.

“We are enthusiastic about our new corporate headquarters in New Jersey and tapping into its deep scientific and biomedical talent along with the area’s strong financial investment community,” said RenovaCare CEO Mr. Alan L. Rubino.

“Our new laboratory facilities in Berlin, Germany are staffed with experts in regenerative product development and bioengineering sectors. We will also continue to work in conjunction with StemCell Systems on the next iterations of RenovaCare technology in the same place where our SkinGun™ technology was originally conceived,” concluded Mr. Rubino,

The RenovaCare team continues to grow as it welcomes its newest member, Dr. Katrin Zeilinger, the former Head of the Bioreactor Group at the Berlin-Brandenburg Center for Regenerative Therapies,

supporting the CellMist™ solution.

Dr. Zeilinger will be working under the guidance of Dr. Roger Esteban-Vives, Vice President of Research and Product Development, who leads the engineering, product testing and laboratory work at RenovaCare labs in Berlin. There, Dr. Zeilinger will be involved in new product development, technology validation and performing laboratory testing related to the behavior of cells under various conditions.

About RenovaCare

RenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body's largest organ, the skin. The company's flagship technology, the CellMist™ System, uses its patented SkinGun™ to spray a liquid suspension of a patient's stem cells – the CellMist™ Solution – onto wounds.

RenovaCare is developing its CellMist™ System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.

RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Company's planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.

For additional information, please call Amit Singh at: 888-398-0202 or visit: https://renovacareinc.com

To receive future press releases via email, please visit: https://renovacareinc.com/investors/register/

Follow us on LinkedIn: https://www.linkedin.com/company/renovacare-inc-/

Follow us on Twitter: https://twitter.com/RenovaCareInc

Follow us on Facebook: https://www.facebook.com/renovacarercar

using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first. We encourage investors, the media, and others interested in the company to review the information we post on the company's website and the social media channels listed below:

- *LinkedIn*
- *Facebook*
- *Twitter*

* This list may be updated from time to time.

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the "Company") believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Company's product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative

litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

LATEST

EDITORIAL

Medicare Negotiated Drug Prices Are Hollow Victory for Biden, Harris

Greg Slabodkin

LAYOFFS

Lykos to Slash 75% of Workforce Following FDA Rejection

Heather McKenzie

INFECTIOUS DISEASE

Pfizer, BioNTech's Mixed Phase III Data Sets Back COVID-Flu Vaccine Candidate

Tristan Manalac

REGULATORY

AstraZeneca's Imfinzi Scores Lung Cancer Wins With FDA's NSCLC Approval, SCLC Priority Review

Tristan Manalac

FEATURED STORIES

POLICY

IRA-Negotiated Drug Prices as Expected but Savings Not as Great as CMS Says

Greg Slabodkin

BUSINESS

Biotech Industry Overcomes Slump, Adapts to New Normal

Ana Mulero

EARNINGS

Q2 Recap: Smooth Sailing for Some, but COVID Cliff and Vaccine Issues Thwart Others

Tyler Patchen

OBESITY

5 Obesity Readouts to Watch in the Second Half of 2024

Heather McKenzie

MORE ON THIS TOPIC

JOB TRENDS

Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report

June 6, 2024 . 3 min read . Greg Slabodkin

DRUG DEVELOPMENT

Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial

BUSINESS

BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases

April 29, 2024 . 2 min read . Tyler Patchen

BUSINESS

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

EXPLORE

News

Jobs

Career Advice

Newsletters

Podcasts

Webinars

Reports

Companies

NextGen Class of 2024

Best Places to Work

HOTBEDS

Biotech Bay

Biotech Beach

BioCapital

BioMidwest

Bio NC

BioForest

Genetown

Pharm Country

Lone Star Bio

ABOUT

About Us

Editorial

Join Our Team

Support

MORE

Employer Login

Post Jobs

Employer Resources

Advertise

Feedback

Privacy Policy

Submit a Press Release

RSS Feeds

Feedback